URGN
insider transactionsUroGen Pharma Ltd. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-30.1K
0 buy · 30.1K sell
Net value · 365d
-$735.0K
$0 in · $735.0K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
8
0 buy · 30.1K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Chief Medical Officer
$0
10.0K sh
Own New
-
Sell·S
Chief Medical Officer
$142.6K
5.2K sh · $27.30
Own -4%
-
Exercise·M
Chief Medical Officer
—
10.0K sh
Own +7%
-
Exercise·M
Director
$0
2.0K sh
Own New
-
Exercise·M
Director
—
2.0K sh
Own +50%
-
Sell·S
Chief Medical Officer · 10b5-1
$300.0K
10.0K sh · $30.00
Own -7%
-
Sell·S
Chief Medical Officer
$72.6K
3.7K sh · $19.69
Own -2%
-
Sell·S
Chief Medical Officer
$36.3K
1.8K sh · $19.69
Own -1%
-
Sell·S
Chief Medical Officer
$36.3K
1.8K sh · $19.69
Own -1%
-
Sell·S
General Counsel
$63.3K
3.2K sh · $19.69
Own -5%
-
Sell·S
General Counsel
$31.7K
1.6K sh · $19.69
Own -3%
-
Sell·S
General Counsel
$52.3K
2.7K sh · $19.69
Own -5%
-
Grant·A
Chief Medical Officer
$0
20.0K sh
Own New
-
Exercise·M
Chief Medical Officer
$0
3.3K sh
Own New
-
Exercise·M
Chief Medical Officer
$0
6.7K sh
Own +100%
-
Exercise·M
Chief Medical Officer
$0
3.3K sh
Own +333300%
-
Exercise·M
Chief Medical Officer
—
3.3K sh
Own +2%
-
Exercise·M
Chief Medical Officer
—
6.7K sh
Own +5%
-
Exercise·M
Chief Medical Officer
—
3.3K sh
Own +2%
-
Grant·A
Chris Degnan KEY
Chief Financial Officer
$0
32.6K sh
Own New
-
Grant·A
General Counsel
$0
32.6K sh
Own New
-
Exercise·M
General Counsel
$0
6.7K sh
Own New
-
Exercise·M
General Counsel
$0
3.3K sh
Own +100%
-
Exercise·M
General Counsel
$0
5.5K sh
Own New
-
Exercise·M
General Counsel
—
6.7K sh
Own +15%
-
Exercise·M
General Counsel
—
3.3K sh
Own +6%
-
Exercise·M
General Counsel
—
5.5K sh
Own +11%
-
Grant·A
Chief Executive Officer
$0
153.2K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 8, 2026 | Mark Schoenberg | Exercise M | 10.0K | $0 |
| Jun 8, 2026 | Mark Schoenberg | Sell S | 5.2K | $142.6K |
| Jun 8, 2026 | Mark Schoenberg | Exercise M | 10.0K | — |
| May 26, 2026 | James A. Robinson Jr. | Exercise M | 2.0K | $0 |
| May 26, 2026 | James A. Robinson Jr. | Exercise M | 2.0K | — |
| May 8, 2026 | Mark Schoenberg 10b5-1 | Sell S | 10.0K | $300.0K |
| Feb 3, 2026 | Mark Schoenberg | Sell S | 3.7K | $72.6K |
| Feb 3, 2026 | Mark Schoenberg | Sell S | 1.8K | $36.3K |
| Feb 3, 2026 | Mark Schoenberg | Sell S | 1.8K | $36.3K |
| Feb 3, 2026 | Jason Drew Smith | Sell S | 3.2K | $63.3K |
| Feb 3, 2026 | Jason Drew Smith | Sell S | 1.6K | $31.7K |
| Feb 3, 2026 | Jason Drew Smith | Sell S | 2.7K | $52.3K |
| Jan 31, 2026 | Mark Schoenberg | Grant A | 20.0K | $0 |
| Jan 31, 2026 | Mark Schoenberg | Exercise M | 3.3K | $0 |
| Jan 31, 2026 | Mark Schoenberg | Exercise M | 6.7K | $0 |
| Jan 31, 2026 | Mark Schoenberg | Exercise M | 3.3K | $0 |
| Jan 31, 2026 | Mark Schoenberg | Exercise M | 3.3K | — |
| Jan 31, 2026 | Mark Schoenberg | Exercise M | 6.7K | — |
| Jan 31, 2026 | Mark Schoenberg | Exercise M | 3.3K | — |
| Jan 31, 2026 | Chris Degnan KEY | Grant A | 32.6K | $0 |
| Jan 31, 2026 | Jason Drew Smith | Grant A | 32.6K | $0 |
| Jan 31, 2026 | Jason Drew Smith | Exercise M | 6.7K | $0 |
| Jan 31, 2026 | Jason Drew Smith | Exercise M | 3.3K | $0 |
| Jan 31, 2026 | Jason Drew Smith | Exercise M | 5.5K | $0 |
| Jan 31, 2026 | Jason Drew Smith | Exercise M | 6.7K | — |
| Jan 31, 2026 | Jason Drew Smith | Exercise M | 3.3K | — |
| Jan 31, 2026 | Jason Drew Smith | Exercise M | 5.5K | — |
| Jan 31, 2026 | Elizabeth A. Barrett KEY | Grant A | 153.2K | $0 |
About URGN insider trading
This page tracks insider transactions for UroGen Pharma Ltd. (URGN) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.